T cells in systemic sclerosis: A reappraisal

Rheumatology (United Kingdom)

Volumn 51, Issue 9, 2012, Pages 1540-1549

  O'Reilly, Steven ^a   Hügle, Thomas ^a   Van Laar, Jacob M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Autoimmunity; Fibrosis; IL 6; Systemic sclerosis; T cells; Tocilizumab

Indexed keywords

CDP 6038; CLAZAKIZUMAB; CYTOKINE; FRESOLIMUMAB; HUMAN MONOCLONAL ANTIBODY; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; LEBRIKIZUMAB; METELIMUMAB; PASCOLIZUMAB; PLACEBO; SILTUXIMAB; SIRUKUMAB; TOCILIZUMAB; TRALOKINUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOLOGICAL THERAPY; CELL INTERACTION; CYTOKINE PRODUCTION; CYTOLOGY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; FIBROSING ALVEOLITIS; FIBROSIS; HISTOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY CARCINOMA; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; TH17 CELL; TH2 CELL;

AUTOIMMUNITY; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CYTOKINES; FIBROBLASTS; FIBROSIS; HUMANS; INTERLEUKINS; SCLERODERMA, SYSTEMIC; TH2 CELLS; TRANSCRIPTION FACTORS;

EID: 84865318866     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes090     Document Type: Review

References (84)

1. Fleischmajer R, Perlish JS, Reeves JRT. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977;20:975-84.
2. Nathan C, Ding A. Nonresolving inflammation. Cell 2010; 140:871-82.
3. Klareskog L, Gustafsson R, Scheynius A, Hällgren R. Increased expression of platelet-derived growth factor type b receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990;33:1534-41.
4. Higashi-Kuwata N, Jinnin M, Makino T et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010; 12:R128.
5. Sunderkötter C, Riemekasten G. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatology 2006;45: iii33-5.
6. Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheum 2006;2: 679-85.
7. Phelps RG, Daian C, Shibata S, Fleischmajer R, Bona CA. Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice. J Autoimmun 1993;6:701-18.
8. Huaux F, Liu T, McGarry B et al. Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis. J Immunol 2003;171:5470-81.
9. Westermann RS, Rieber EP, Frank WK-H. Th2 cells as effectors in postirradiation pulmonary damage preceding fibrosis in the rat. Int J Radiat Biol 1999;75:629-38.
10. Isaacs JD, Hazleman BL, Chakravarty K et al. Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol 1996;23:1103-6.
11. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 2001; 40:84-8.
12. Kuwana M, Medsger T, Wright T. T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. J Immunol 1995;155:2703-14.
13. Becker MO, Brückner C, Scherer HU et al. The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann Rheum Dis 2011;70:1340-1.
14. van Laar JM, Farge D, Tyndall A. Stem cell transplantation: a treatment option for severe systemic sclerosis? Ann Rheum Dis 2008;67:iii35-8.
15. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
16. Prescott RJ, Freemont AJ, Jones CJP, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
17. Roumm AD, Whiteside TL, Medsger TA, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Arthritis Rheum 1984;27:645-53.
18. Abraham D, Lupoli S, McWhirter A et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991;34:1164-72.
19. Kalogerou A, Gelou E, Mountantonakis S et al. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005;64:1233-5.
20. Fiocco U, Rosada M, Cozzi L et al. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis 1993;52:272-7.
21. Klein S, Kretz CC, Ruland V et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 2011;70: 1475-81.
22. Papp G, Horvath I, Barath S et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 2011;40: 205-10.
23. Mosmann T, Cherwinski H, Bond M, Giedlin M, Coffman R. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
24. Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol 2011;300:G723-8.
25. Seno H, Miyoshi H, Brown SL et al. Efficient colonic mucosal wound repair requires Trem2 signaling. Proc Natl Acad Sci USA 2009;106:256-61.
26. Alonso MN, Wong MT, Zhang AL et al. TH1, TH2, and TH17 cells instruct monocytes to differentiate into specialized dendritic cell subsets. Blood 2011;118:3311-20.
27. Ramsdell F, Fowlkes B. Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance. Science 1990;248:1342-8.
28. Ramsdell F, Lantz T, Fowlkes B. A nondeletional mechanism of thymic self tolerance. Science 1989;246: 1038-41.
29. Appleman LJ, Boussiotis VA. T cell anergy and costimulation. Immunol Rev 2003;192:161-80.
30. Dieudé P, Guedj M, Truchetet ME et al. Association of the CD226 Ser307 variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum 2011;63: 1097-105.
31. Shibuya A, Campbell D, Hannum C et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996;4:573-81.
32. Shibuya K, Shirakawa J, Kameyama T et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med 2003;198:1829-39.
33. Bottino C, Castriconi R, Pende D et al. Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003;198:557-67.
34. Nabekura T, Shibuya K, Takenaka E et al. Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice. Proc Natl Acad Sci USA 2010;107:18593-8.
35. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro-and anti-inflammatory forces in autoimmune arthritis. Rheumatology 2009;48:602-6.
36. Valencia X, Stephens G, Goldbach-Mansky R et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006;108: 253-61.
37. Klein S, Kretz CC, Ruland V et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 2010; 70:1475-81.
38. Slobodin G, Ahmad MS, Rosner I et al. Regulatory T cells (CD4+CD25brightFoxP3+) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 2010;261:77-80.
39. Radstake TRDJ, van Bon L, Broen J et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFß expression. PLoS ONE 2009;4: e5981.
40. Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol 2009;18:727-9.
41. Kopf M, Gros GL, Bachmann M et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245-8.
42. Sharma S, MacLean J, Pinto C, Kradin R. The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury. Am J Respir Crit Care Med 1996;154:193-200.
43. Salmon-Ehr V, Serpier H, Nawrocki B et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures: potential role in fibrosis. Arch Dermatol 1996;132:802-6.
44. Luzina IG, Atamas SP, Wise R et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum 2003;48:2262-74.
45. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479-85.
46. Ong C, Wong C, Roberts CR, Teh H-S, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998;28:2619-29.
47. McGaha T, Saito S, Phelps RG et al. Lack of skin fibrosis in tight skin (Tsk) mice with targeted mutation in the interleukin-4R[alpha] and transforming growth factor-[beta] genes. 2001;116:136-43.
48. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor a, and interferon-? levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
49. Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH. Dual roles of IL-4 in lung injury and fibrosis. J Immunol 2003; 170:2083-92.
50. Atamas SP, Luzina IG, Dai H, Wilt SG, White B. Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 2002;168: 1139-45.
51. Valentini G, Romano MF, Naclerio C et al. Increased expression of CD40 ligand in activated CD4+T lymphocytes of systemic sclerosis patients. J Autoimmun 2000; 15:61-6.
52. Wills-Karp M, Luyimbazi J, Xu X et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282: 2258-61.
53. Aversa G, Punnonen J, Cocks BG et al. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. J Exp Med 1993;178: 2213-18.
54. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie ANJ. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 2000;164: 2585-91.
55. Kaviratne M, Hesse M, Leusink M et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-b independent. J Immunol 2004;173:4020-9.
56. Lee CG, Homer RJ, Zhu Z et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor ß1. J Exp Med 2001;194: 809-22.
57. Zhu Z, Homer RJ, Wang Z et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779-88.
58. Belperio JA, Dy M, Burdick MD et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002;27: 419-27.
59. Oriente A, Fedarko NS, Pacocha SE et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000;292:988-94.
60. Rankin AL, Mumm JB, Murphy E et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 2010;184: 1526-35.
61. Parel Y, Aurrand-Lions M, Scheja A et al. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 2007;56: 3459-67.
62. Atamas SP, Yurovsky VV, Wise R et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42:1168-78.
63. Fuschiotti P, Medsger TA, Morel PA. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 2009;60:1119-28.
64. Medsger TA, Ivanco DE, Kardava L et al. GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum 2011;63: 1738-47.
65. van Kooten C, Rensink I, Pascual-Salcedo D, van Oers R, Aarden L. Monokine production by human T cells; IL-1 alpha production restricted to memory T cells. J Immunol 1991;146:2654-58.
66. Lorré K, Kasran A, Van Vaeck F, de Boer M, Ceuppens JL. Interleukin-1 and B7/CD28 interaction regulate interleukin-6 production by human T cells. Clin Immunol Immunopathol 1994;70:81-90.
67. Ferran C, Dautry F, Mérite S et al. Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest 1994;93:2189-96.
68. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology 1999;38:612-17.
69. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
70. Gudbjörnsson B, Hällgren R, Nettelbladt O et al. Phenotypic and functional activation of alveolar macrophages, T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjögren's syndrome. Ann Rheum Dis 1994;53:574-9.
71. Yoshizaki A, Yanaba K, Ogawa A et al. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011;63: 3575-85.
72. Saito F, Tasaka S, Inoue K-I et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 2008;38:566-71.
73. Koch AE, Kronfeld-Harrington LB, Szekanecz Z et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Pathobiology 1993;61:239-46.
74. Gambichler T, Skrygan M, Labanski AA et al. Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma. Regul Pept 2011;170: 4-6.
75. Barnes TC, Spiller DG, Anderson ME, Edwards SW, Moots RJ. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis? Ann Rheum Dis 2011; 70:366-72.
76. Rincón M, Anguita J, Nakamura T, Fikrig E, Flavell RA. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T Cells. J Exp Med 1997;185: 461-70.
77. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1a from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999;103:1253-60.
78. Kitaba S, Murota H, Terao M et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012;180:165-76.
79. Jones SA, Novick D, Horiuchi S et al. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 1999;189:599-604.
80. Beriou G, Costantino CM, Ashley CW et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009;113:4240-9.
81. Divekar AA, Khanna D, Abtin F et al. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4+ T cells in the broncho-alveolar lavage of patients with systemic sclerosis. Clin Immunol 2011;141: 293-303.
82. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005;175: 3463-8.
83. Denton CP, Merkel PA, Furst DE et al. Recombinant human anti-transforming growth factor ß1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33.
84. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365: 1088-98.